.
MergerLinks Header Logo

Announced

Completed

Sema4 completed the acquisition of GeneDx from OPKO Health for $623m.

Financials

Edit Data
Transaction Value£455m
Consideration TypeCash, Ordinary Shares, Contingent Deferred Consideration
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Single Bidder

Biotechnology

United States

Acquisition

Friendly

Private

Majority

Domestic

genomic testing

Completed

Synopsis

Edit

Sema4, an AI-driven genomic and clinical data intelligence platform company, completed the acquisition of GeneDx, a provider of genomic testing and analysis, from OPKO Health, a multinational biopharmaceutical and diagnostics company, for $623m. "This acquisition gives us the opportunity to accelerate the use of genomics as standard of care by providing a deeper menu of precision medicine solutions to our health system partners to better meet their clinical needs," Eric Schadt, Sema4 Founder and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US